Large-scale cancer sequencing studies have uncovered dozens of mutations critical to cancer initiation and progression. However, a significant proportion of genes linked to tumor propagation remain hidden, often due to noise in sequencing data confounding low frequency alterations. Further, genes in networks under purifying selection (NPS), or those that are mutated in cancers less frequently than would be expected by chance, may play crucial roles in sustaining cancers but have largely been overlooked. We describe here a statistical framework that identifies genes that have a first order protein interaction network significantly depleted for mutations, to elucidate key genetic contributors to cancers. Not reliant on and thus, unbiased by, the gene of interest's mutation rate, our approach has identified 686 putative genes linked to cancer development. Comparative analysis indicates statistically significant enrichment of NPS genes in previously validated cancer vulnerability gene sets, while further identifying novel cancer-specific candidate gene targets. As more tumor genomes are sequenced, integrating systems level mutation data through this network approach should become increasingly useful in pinpointing gene targets for cancer diagnosis and treatment.
the single gene level. In these studies, genes were systematically perturbed, and the resulting effect on cancer cell line growth was recorded (Garraway and Lander, 2013; Bass et al., 2009; Lopez and Hanahan, 2002; Etemadmoghadam et al., 2010; Ramsay and Gonda, 2008; Mansouri et al., 1998; Okhrimenko et al., 2005; Kim and Sabatini, 2004) . More recently, genome-wide RNAi knockdown and CRIPSR-Cas9 knockout experiments have expanded the study of cancer vulnerabilities in a wide range of cell lines (Cheung et al., 2011; Tsherniak et al., 2017; Wang et al., 2015) . This approach has been translated to the clinical stage, by generating a cell line from a clinical tumor sample, investigating this cell line using a combined RNAi and CRISPR-Cas9 approach, and subsequently recommending treatment based on patient-specific vulnerabilities (Hong et al., 2016) . However, experimentally generating a comprehensive catalog of vulnerabilities across different cancer cell lines requires considerable resources (e.g. an estimated 600-5,000 samples per tumor type for near-saturation, depending on background mutation frequency) (Lawrence et al., 2014) .
Tumor cells accumulate large amounts of passenger mutations as a consequence of unchecked proliferation, genotoxic stress, and defects in the DNA repair machinery. These mutations do not participate in initiating the tumor, and passenger mutation rates can be modeled as randomly distributed across the tumor genome when considering factors such as sequence composition, position, replication timing, transcription-coupled DNA damage repair, and mutation hotspots (Lawrence et al., 2014; Weghorn and Sunyaev, 2017) . It should therefore be possible to identify genes that are essential to the proliferation of cancer cells directly from cancer mutation data, by looking for genes that significantly lack passenger mutations. Several computational methods have accounted for the potential role of passenger mutations in the search for cancer dependencies. Cancer Vulnerabilities Unveiled by Genomic Loss (CYCLOPS) has used available expression data to find genes with partial copy number loss, yielding cells that are vulnerable to their knockouts (Nijhawan et al., 2012) . Further, a study on synthetic lethality has analyzed The Cancer Genome Atlas dataset to find mutually exclusive loss-of-function (LoF) gene sets (Ryan et al., 2014) . A more recent Bayesian inference approach has successfully found cancer driver genes, but has so far detected only subtle signal from genes under purifying selection in the tumors (Weghorn and Sunyaev, 2017) .
Despite these studies' advancements, the statistical detection of infrequently mutated or preserved genes is strongly confounded by the high background copy number and mutation rates in cancer genomes, potentially unfiltered germline variants in cancer sequencing data, and heterogeneity in mutation rates along the genome, specifically in the context of a single cancer cell. This means that even the most sophisticated methods to detect signals of purifying selection at the gene level are currently underpowered (Tsherniak et al., 2017; Weghorn and Sunyaev, 2017) In this work, we provide a more robust approach to computationally detect cancer vulnerability genes from cancer genomes, by aggregating weak signals of negative selection across a gene's first order protein-protein interaction network. We present a statistic, Network Purifying Selection (NPS), which identifies genes that have a network significantly depleted for mutations, indicating that the gene itself is likely to be a vulnerability gene. We applied NPS to 4,742 tumor genomes from 21 tumor types to identify 686 genes with a significant NPS score. Our approach corroborates previously documented studies on cancer dependencies but also identifies a novel set of genes that are likely cancer-specific vulnerabilities. The NPS code is available at www.lagelab.org, and the approach we develop here should become increasingly useful as more cancer genomes are sequenced in the future. network (Lage et al., 2007; Li et al., 2016) , that has been used in dozens of genetic studies, including in the 1000 Genomes Project (Khurana et al., 2013) , to calculate the signal of purifying selection in a gene's functional proteinprotein interaction network. Since we specifically wanted a statistic to determine the predictive signal of purifying selection in a gene's network, we excluded any mutation information on the gene itself in the NPS score calculation.
This specific design choice enables NPS to complement any other gene-based method to identify cancer vulnerabilities.
To benchmark the NPS statistic and to test if it accurately classifies cancer vulnerabilities, we defined a set of well established genes from three existing datasets: copy number alterations yielding cancer liabilities owing to partial loss (CYCLOPS), aggregate RNAi gene knockdown data analyzed by DEMETER, and CRISPR-induced LoF essentiality genes from Wang et al. (Figure 1a) . Briefly, the CYCLOPS method has identified 56 cancer-specific vulnerability genes by analyzing the effect on tumor growth of knocking out the wild type allele of a gene where the other copy has been lost due to copy number changes in the cancer cells (Nijhawan et al., 2012) . DEMETER models gene knockdown effects within the data and computationally subtracts off-target effects to find cancer dependencies (Tsherniak et al., 2017) . The CRISPR-induced LoF genes are a set of cell-essential genes required for proliferation and survival in a human cancer cell line (Wang et al., 2015) . Table 1 ).
To estimate how well the NPS score predicts vulnerability genes and to see if genes that do not pass the significance cutoff might still be valuable candidates, we also calculated receiver operating characteristic (ROC) curves for all three sets. AUCs were 0.68 (P=0.153), 0.677, and 0.645 These findings indicate that genes significant in the NPS are enriched for previously associated cancer genes.
The NPS score thus accurately distinguishes CYCLOPS, DEMETER, and cancer cell-essential genes from other genes covered by interactions in the InWeb database.
Predicting Network Purifying Selection candidates from tumor genomes
To test if the NPS statistic can predict new vulnerability genes from existing cancer genome data, we calculated NPS scores for all genes that had at least one high-confidence protein interaction in InWeb. We declared genes as significant at a false discovery rate of Q ≤ 0.1 using the pan-cancer cohort of 4,742 tumors. The pooled set (named NPS5000, Supplementary Table 2) contains all unique genes that were significant in the pan-cancer analysis or in at least one of the 21 tumor types. NPS5000 is comprised of 686 genes, many of which are linked to known cancer biology. Figures 3 and 4, Supplementary Table 3 ).
As expected, many of these processes are found in subsets of living cells, but also in the hallmarks of cancer.
Network Purifying Selection detects cancerspecific vulnerabilities
NPS should in theory identify both genes that specifically are cancer vulnerabilities, but also genes that are generally under purifying selection in human populations, because they are essential to both normal and cancer cells. To dissect this phenomenon, we tested the overlap of our NPS5000 set with genes from population genetic studies that are known to have a high probability of being intolerant to LoF mutations (Samocha et al., 2014) (Figure 2) . Specifically, we overlapped the NPS5000 set with genes from the Exome Ag- Table 2 ).
Tumor essentiality of NPS candidates
We assessed the impact of knockouts of three gene sets on the growth of 216 cancer cell lines. These sets comprise all
ExAC genes (Background), the overlapping NPS and ExAC vulnerability genes, and the non-ExAC NPS vulnerability genes (e.g. those genes specific to cancer dependencies) ( Figure 3) . We used the cell proliferation data compiled through Project Achilles, which catalogues the genetic vulnerabilities of genomically characterized cancer cell lines through individual gene knockouts using the CRISPR-Cas9 system (Cowley et al., 2014) ; internal Broad data set). Statistically significant tumor growth aberrations due to NPS gene knockouts, as determined by Achilles gene knockout studies (Meyers et al., 2017) , indicate the direct relevance of these genes in sustaining tumor proliferation.
Knockouts of NPS genes change tumor growth rate, and NPS only, non-ExAC gene knockouts (those that are putative cancer-specific vulnerabilities) affect tumor growth even more, suggesting the identified genes' key role in tumor development.
The pan-cancer NPS-imputed gene analysis presented here unveils that genes in networks under purifying selection in cancers could be harnessed for cancer treatment.
The existence of FDA-approved drugs targeting these newly identified cancer vulnerabilities (Supplementary Table 4) supports the claim for repurposing therapies, enabling a shortened timeline to treat otherwise intractable cancers.
Methods
Calculating the network purifying selection score 
Classifying cancer vulnerability genes
For each gene represented in InWeb (12,507 or 67% of the estimated genes in the genome), we used the genespecific NPS probability to classify it as a cancer vulnerability gene or not. True positive genes were a set of CY-CLOPS, DEMETER, and CRISPR-induced cell-essential cancer genes. Specifically, we selected 56 genes categorized as CYCLOPs genes as described in (Nijhawan et al., 2012) , and DEMETER genes were defined as the 769 genes that were differentially required in subsets of the analyzed cell lines at a threshold of six SDs from the mean (Tsherniak et al., 2017) . True negatives were defined as all genes in
InWeb that were not in these three sets, which is likely conservative, as we currently lack the power to confidentially estimate the number of potential vulnerabilities. We used the NPS probability as the classifier and calculated the AUC for each gene set.
Testing the robustness of the NPS approach
A more in depth evaluation has been performed in Horn et al. Here, to assure that the permutation holds up, we limited testing to compare permutation methods (random permutation vs. connectivity aware). We ran the full analysis using both approaches and compared the quantile-quantile plots.
This analysis confirmed that ignoring the interaction structure of the immediate neighborhood significantly depletes the signal (Supplementary Figure 1) .
Generating the NPS5000 set
NPS probabilities were determined for every gene in InWeb that was covered by interaction data using 10 6 permutations. The FDR Q values were calculated as described by
Benjamini and Hochberg, based on the nominal P values controlled for 12,507 hypotheses. We performed NPS analyses with the pan-cancer Q values, as well as Q values from each of the 21 tumor types for which they were available.
As it is a technical limitation of the NPS approach that it is currently not possible to make 5.5 × 10 6 network permutations, we could not create a dataset where we correct for all 12, 500 × 22 hypotheses tested in the NPS5000 set.
Detecting cancer-specific vulnerabilities
To expand the known catalog of vulnerabilities, we tested whether our approach could predict both putative and novel, cancer-specific vulnerability genes directly from tumor and exome sequencing data (ExAC). We filtered for ExAC genes with pLI scores ≥ 0.9 and checked for their overlap with NPS genes, as well as for NPS genes that did not fall in the highly potent ExAC gene LOF list, for cancer-specific targets.
Dissecting tumor gene essentiality
We tested the effects of NPS gene knock-outs on cancer 
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